Arcutis Biotherapeutics, Inc.
31.20USD
-1.0000 (-3.11%)
Not enough data yet
A reading needs 5 members, each at least 14 days old with a track record on this site (simulated portfolios and calls), who shared a take in the last 30 days; 2 of them need a strong record.
Sign in to share your take on ARQT.
Revenue
| (USD) | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|
| FY | 3.7M | 59.6M | 196.5M | 376.1M | 538.6M | 695.7M |
| Q1 | 0.0 | 2.8M | 49.6M | 65.8M | 105.4M | — |
| Q2 | 0.0 | 5.2M | 30.9M | 81.5M | 129.9M | — |
| Q3 | 725.0K | 38.1M | 44.8M | 99.2M | 142.6M | — |
| Q4 | 3.0M* | 13.5M* | 71.4M* | 129.5M* | 160.7M | — |
Revenue
| (USD) | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|
| FY | -5.66 | -3.78 | -1.16 | -.130 | .425 | 1.34 |
| Q1 | -1.27 | -1.31 | -.320 | -.000 | -.000 | — |
| Q2 | -1.31 | -1.16 | -.420 | -.130 | .110 | — |
| Q3 | -1.89 | -.730 | -.330 | .060 | .168 | — |
| Q4 | -1.31* |
Fiscal period: Reported, Estimated. Reported figures: SEC filings (EDGAR). Estimates are sell-side consensus for periods that have not reported. Cells marked * were synthesized from the annual filing less the year-to-date figures, because the quarter was not filed on its own. Earnings per share are restated onto today's share basis, so a period before a stock split is comparable with the ones after it.
Revenue to net income
| -.956* |
| -.089* |
| .137* |
| .232 |
| — |
Debt level and coverage